Purpose and Context
The overall purpose of M&E is to measure program effectiveness, efficiency, and equity, as well as “ identify problem areas, gather lessons learned and improve over-all performance.” The M&E Plan of PhilPACT will take into consideration the following:
Administrative Order No. 2008-0016 that describes the guidelines on monitoring and evaluation for equity and effectiveness (ME3) in support of the health sector strengthening through Fourmula One for Health;
current NTP monitoring and evaluation structure and system as described in the 2005 MOP;
the Stop TB Partnership’s recommended M&E as contained in the “Compendium of
Indicators for Monitoring and Evaluating National Tuberculosis Programs” issued in August 2004; and
the planning framework of PhilPACT.
Specifically, the M&E will be based on the vision, goals, objectives as well as performance targets and activities presented in an earlier section. This is coherent with the ME3 framework which is a DOH-developed system that aims to ”determine if reforms have equitably and effectively achieved goals in the health system.” It presumes that the conduct of planned activities will lead to the achievement of the performance targets which in turn will contribute to the accomplishment of the objectives, and eventually the planned outcomes and impact.
Implementing Arrangements for M&E The National Coordinating Committee will be responsible for overseeing the implementation, monitoring, and evaluation of PhilPACT. The Health Policy Development and Planning Bureau (HPDPB) of the Department of Health will be the technical unit responsible for the development and implementation of the monitoring and evaluation system for PhilPACT in accordance with the ME3. It will be assisted by IDO-NCDPC and the NEC of the DOH. With the assistance of Global Fund, NEC will develop the monitoring and evaluation for TB, HIV/
AIDS, and malaria, hence, PhilPACT’s monitoring and evaluation system will be further refined and regularly updated. Other units that will participate are DOTS facilities, both public and private, LGUs, international and local partners, and other offices of the DOH.
Indicators, Data Sources, and Collection Methodologies
Indicators include programmatic or technical indicators and sectoral indicators. Indicators are also categorized into impact, outcome, output, and process.
Primary and secondary data will be collected from various sources using different data collection methodologies to determine the progress of indicators. The impact of the plan, as measured by the TB prevalence and TB mortality rates, will be tracked using population surveys and studies. The 4th National Prevalence Survey will be done in 2014 while the National Drug Resistance Survey will be repeated in 2011. TB mortality rate will be calculated from data collected from vital registration by the National Statistics Office and reported by NEC in its annual Philippine Health Statistics. Recognizing the limitation of the NSO-collected data, a TB mortality study will be done in 2012. To track progress towards the MDG goals, the prevalence rate and mortality rate released by WHO in its annual surveillance report will be utilized.
Outcome indicators such as the case detection rate, treatment success rate, cure rate and default rate will be computed based on the quarterly case findings and case holding reports regularly submitted to IDO by various DOTS facilities, both public and private, through the provincial/city health office and Center for Health Development (CHD). These reports are based on the TB register and laboratory register maintained by all DOTS facilities. Timeliness and quality of data will be enhanced through the integrated electronic TB information system and regular feedback. Data on the number of MDR-TB cases detected and treated and their treatment outcome will be collected and submitted by the PMDT treatment centers to IDO through the CHDs in coordination with TDFI. The NPS and NDHS will also generate data on the health-seeking behavior of the TB symptomatic.
Process indicators that are not included in the routine program performance report will be collected through local and international partners.
For example, data on private sector participation such as number of LGUs with DOTS referral network
and number of private practitioners trained are regularly collected and reported by the TB control projects managed by PhilCAT and TB LINC. Other DOH units, such as the Bureau of Local Health Development, will provide NTP data on the LGU scorecard, the National TB Reference Laboratory of the Research Institute of Tropical Medicine on TB laboratory indicators, the Bureau of International Health Cooperation (BHIC) on TB financing from FAPs and their activities, and the Finance Service on the performance grant. CUP partners will provide information on the initiatives for their constituents such as the DOJ and DILG for the inmates with TB. Financing information will be generated from TB subaccounts and the DOH resource tracking information. Other sources of data will be from:
NTP program implementation reviews, held three times a year at the national level and semiannually at the regional level, annual PIRs done for specific initiative such as PPM, TB laboratory, and PMDT;
Joint Program Review organized by WHO; and
monitoring reports of NTP and other partners.
A midterm evaluation that will be participated in by stakeholders will be performed in early 2013 and a terminal evaluation will be conducted in early 2016.
Information will be encoded into a digital format and will be stored electronically and on paper.
Quality control of data will be done at all levels
Data Analysis, Dissemination, and Use The IDO and NEC will be responsible for ensuring that the needed information from the various sources are collected, submitted, consolidated, and analyzed. HPDPB will help IDO and NEC enhance the system for regular reporting by partners and dissemination/use of results.
HPDPB will also ensure that a web site that contains all the TB information related to PhilPACT will be developed, updated, and sustained and that an annual report that analyzes the progress of the
strategic plan implementation will be issued. The report will be submitted to the DOH management and disseminated to partners. Stakeholders’
meetings will be conducted after the midterm and terminal evaluation to present and discuss results.
Capacity-building activities to ensure effective use of information from the M&E are explained in the section on Strategy 2.
Annex 4 describes in detail the indicators, sources of data, data collection methodologies, and frequency of reporting for each performance indicator/target.